Gc-globulin in liver disease

Danish Medical Bulletin

Volumn 55, Issue 3, 2008, Pages 131-146

  Schiødt, Frank Vinholt ^a,b,c  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ALBUMIN; COMPLEMENT COMPONENT C5A RECEPTOR; MACROPHAGE ACTIVATING FACTOR; PARACETAMOL; VITAMIN D BINDING PROTEIN;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CELL DEATH; CHRONIC LIVER DISEASE; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG OVERDOSE; EXTRACELLULAR MATRIX; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CELL; LIVER DISEASE; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; MULTIPLE ORGAN FAILURE; NATURAL KILLER CELL; NEPHELOMETRY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHYLOGENY; POSTOPERATIVE PERIOD; PREDICTION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SCAVENGING SYSTEM; SURVIVAL; UNITED STATES;

ACTINS; CHRONIC DISEASE; GELSOLIN; HUMANS; LIVER DISEASES; LIVER FAILURE; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MULTIPLE ORGAN FAILURE; PROGNOSIS; VITAMIN D-BINDING PROTEIN;

EID: 53249154945     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (211)

1. Schiødt FV, Bondesen S, Tygstrup N. Serial measurements of serum Gc-globulin in acetaminophen intoxication. Eur J Gastroenterol Hepatol 1995; 7:635-640.
2. Schiødt FV, Bondesen S, Petersen I, Dalhoff K, Ott P, Tygstrup N. Admission levels of serum Gc-globulin: predictive value in fulminant hepatic failure. Hepatology 1996; 23:713-718.
3. Schiødt FV, Ott P, Bondesen S, Tygstrup N. Reduced serum Gc-globulin levels in patients with fulminant hepatic failure: association with multiple organ failure. Crit Care Med 1997; 25(8):1366-1370.
4. Schiødt FV, Bondesen S, Müller K, Rasmussen A, Hjortrup A, Kirkegaard P et al. Reconstitution of the actin-scavenger system after orthotopic liver transplantation: a prospective and longitudinal study. Liver Transpl Surg 1999; 5:310-317.
5. Schiødt FV, Clemmesen JO, Bondesen S, Dahl B, Ott P. Increased turnover of Gc-globulin in patients with hepatic encephalopathy. Scand J Gastroenterol 2001; 36:998-1003.
6. Schiødt FV, Ott P, Tygstrup N, Dahl B, Bondesen S. Temporal profile of total, bound, and free Gc-globulin after acetaminophen overdose. Liver Transpl 2001; 7(8):732-738.
7. Schiødt FV, Rossaro L, Stravitz RT, Shakil AO, Chung RT, Lee WM. Gc-globulin and prognosis in acute liver failure. Liver Transpl 2005; 11(10):1223-1227.
8. Cooke NE, Haddad JG. Vitamin D binding protein (Gc-globulin). Endocr Rev 1989; 10:294-307.
9. Constans J. Group-specific component is not only a vitamin-D-binding protein. Exp Clin Immunogenet 1992; 9:161-175.
10. Haddad JG. Plasma vitamin D-binding protein (Gc-globulin): multiple tasks. J Steroid Biochem Molec Biol 1995; 53:579-582.
11. Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin toxicity. N Engl J Med 1992; 326:1335-1341.
12. Hirschfeld J. Immune-electrophoretic demonstration of qualitative differences in human sera and their relation to the haptoglobins. Acta Pathol Microbiol Scand 1959; 47:160-168.
13. Ray K, Wang X, Zhao M, Cooke NE. The rat vitamin D binding protein (Gc-globulin) gene. Structural analysis, functional and evolutionary correlations. J Biol Chem 1991; 266:6221-6229.
14. Braun A, Kofler A, Morawietz S, Cleve H. Sequence and organization of the human vitamin D-binding protein gene. Biochim Biophys Acta 1993; 1216:385-394.
15. Daiger SP, Miller M, Chakraborty R. Heritability of quantitative variation at the group-specific component (Gc) locus. Am J Hum Genet 1984; 36:663-676.
16. Barragry JM, Corless D, Auton J, Carter ND, Long RG, Maxwell JD et al. Plasma vitamin D-binding globulin in vitamin D deficiency, pregnancy and chronic liver disease. Clin Chim Acta 1978; 87:359-365.
17. Rejnmark L, Lauridsen AL, Brot C, Vestergaard P, Heickendorff L, Nexo E et al. Vitamin D and its binding protein Gc: long-term variability in peri- and postmenopausal women with and without hormone replacement therapy. Scand J Clin Lab Invest 2006; 66(3):227-238.
18. Lauridsen AL, Vestergaard P, Nexo E. Mean serum concentration of vitamin D-binding protein (Gc globulin) is related to the Gc phenotype in women. Clin Chem 2001; 47(4):753-756.
19. Constans J, Arlet P, Viau M, Bouissou C. Unusual sialilation of the serum DBP associated with the Gc 1 allele in alcoholic cirrhosis of the liver. Clin Chim Acta 1983; 130(2):219-230.
20. Brown IR, Carter ND, Sood A. Vitamin D binding globulin phenotypes in liver disease. Clin Chim Acta 1979; 95(1):75-82.
21. Specker BL, Tsang RC, Ho M, Buckley D. Seasonal differences in serum vitamin D binding protein in exclusively breast-fed infants: negative relationship to sunshine exposure and 25- hydroxyvitamin D. J Pediatr Gastroenterol Nutr 1986; 5(2):290-294.
22. Rejnmark L, Lauridsen AL, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L. Diurnal rhythm of plasma 1,25-dihydroxyvitamin D and vitamin D-binding protein in postmenopausal women: relationship to plasma parathyroid hormone and calcium and phosphate metabolism. Eur J Endocrinol 2002; 146(5):635-642.
23. Haefliger DN, Moskaitis JE, Schoenberg DR, Wahli W. Amphibian albumins as members of the albumin, alpha-fetoprotein, vitamin D-binding protein multigene family. J Mol Evol 1989; 29:344-354.
24. Nishio H, Heiskanen M, Palotie A, Belanger L, Dugaiczyk A. Tandem arrangement of the human serum albumin multigene family in the sub-centromeric region of 4q: evolution and chromosomal direction of transscription. J Mol Biol 1996; 259:113-119.
25. Nishio H, Dugaiczyk A. Complete structure of the human α-albumin gene, a new member of the serum albumin multigene family. Proc Natl Acad Sci USA 1996; 93:7557-7561.
26. McLeod JF, Cooke NE. The vitamin D-binding protein, α-fetoprotein, albumin multigene family: detection of transcripts in multiple tissues. J Biol Chem 1989; 264:21760-21769.
27. Lichenstein HS, Lyons DE, Wurfel MM, Johnson DA, McGinley MD, Leidli JC et al. Afamin is a new member of the albumin, a-fetoprotein, and vitamin D-binding protein family. J Biol Chem 1994; 269:18149-18154.
28. Song Y-H, Naumova AK, Liebhaber SA, Cooke NE. Physical and meiotic mapping of the region of human chromosome 4q11-q13 encompassing the human vitamin D binding protein DBP/Gc-globulin and albumin multigene cluster. Genome Res 1999; 9:581-587.
29. Cleve H. The variants of the group-specific component. A review of their distribution in human populations. Isr J Med Sci 1973; 9(9):1133-1146.
30. Safadi FF, Thornton P, Magiera H, Hollis BW, Gentile M, Haddad JG et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 1999; 103:239-251.
31. White P, Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metabol 2000; 11(8):320-327.
32. Verboven C, Bogaerts I, Waelkens E, Rabijns A, Van Baelen H, Bouillon R et al. Actin-DBP: the perfect structural fit? Acta Crystallogr D Biol Crystallogr 2003; 59(Pt 2):263-273.
33. Verboven C, Rabijns A, De Maeyer M, Van Baelen H, Bouillon R, De Ranter C. A structural basis for the unique binding features of the human vitamin D-binding protein. Nat Struct Biol 2002; 9(2):131-136.
34. Kawakami M, Blum CB, Ramakrishnan R, Dell RB, Goodman DS. Turnover of the plasma binding protein for vitamin D and its metabolites in normal human subjects. J Clin Endocrinol Metab 1981; 53:1110-1116.
35. Goldschmidt-Clermont PJ, Van Baelen H, Bouillon R, Shook TE, Williams MH, Nel AE et al. Role of group-specific component (vitamin D binding protein) in clearance of actin from the circulation in the rabbit. J Clin Invest 1988; 81:1519-1527.
36. Dueland S, Blomhoff R, Pedersen JI. Uptake and degradation of vitamin D binding protein and vitamin D binding protein-actin complex in vivo in the rat. Biochem J 1990; 267:721-725.
37. Stossel TP. Contractile proteins in cell structure and function. Ann Rev Med 1978; 29:427-457.
38. Janmey PA, Hvidt S, Kas J, Lerche D, Maggs A, Sackmann E et al. The mechanical properties of actin gels. Elastic modulus and filament motions. J Biol Chem 1994; 269:32503-32513.
39. Stossel TP. From signal to pseudopod. How cells control cytoplasmic actin assembly. J Biol Chem 1989; 264:18261-18264.
40. Stossel TP. On the crawling of animal cells. Science 1993; 260:1086-1094.
41. Carlier M-F. Actin: protein structure and filament dynamics. J Biol Chem 1991; 266:1-4.
42. Janmey P. A slice of the actin. Nature 1993; 364:675-676.
43. Vasconcellos CA, Lind SE. Coordinated inhibition of actin-induced platelet aggregation by plasma gelsolin and vitamin D-binding protein. Blood 1993; 82:3648-3657.
44. Scarborough VD, Bradford HR, Ganguly P. Aggregation of platelets by muscle actin. A multivalent interaction model of platelet aggregation by ADP. Biochem Biophys Res Comm 1981; 100: 1314-1319.
45. Lind SE, Smith CJ. Actin is a noncompetitive plasmin inhibitor. J Biol Chem 1991; 266:5273-5278.
46. Lind SE, Smith CJ. Actin stimulates plasmin generation by tissue and urokinase-type plasminogen activators. Arch Biochem Biophys 1993; 307:138-145.
47. Janmey PA, Lamb JA, Ezzell RM, Hvidt S, Lind SE. Effects of actin filaments on fibrin clot structure and lysis. Blood 1992; 80:928-936.
48. Janmey PA, Lind SE, Yin HL, Stossel TP. Effects of semi-dilute actin solutions on the mobility of fibrin protofibrils during clot formation. Biochim Biophys Acta 1985; 841:151-158.
49. Haddad JG, Harper KD, Guoth M, Pietra GG, Sanger JW. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci USA 1990; 87:1381-1385.
50. Erukhimov JA, Tang ZL, Johnson BA, Donahoe MP, Razzack JA, Gibson KF et al. Actin-containing sera from patients with adult respiratory distress syndrome are toxic to sheep pulmonary endothelial cells. Am J Respir Crit Care Med 2000: 162(1):288-294.
51. Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the vitamin D-binding protein in clearing actio from the circulation. J Clin Invest 1986; 78:736-742.
52. Harper KD, McLeod JF, Kowalski MA, Haddad JG. Vitamin D binding protein sequesters monomeric actin in the circulation of the rat. J Clin Invest 1987; 79:1365-1370.
53. Kwiatkowski DJ, Mehl R, Izumo S, Nadal-Ginard B, Yin HL. Muscle is the major source of plasma gelsolin. J Biol Chem 1988; 263:8239-8243.
54. Sun H-Q, Wooten DC, Janmey PA, Yin HL. The actin side-binding domain of gelsolin also caps actin filaments. Implications for actin filament severing. J Biol Chem 1994; 269:9473-9479.
55. McLaughlin PJ, Gooch JT, Mannherz H-G, Weeds AG. Structure of gelsolin segment 1-actin complex and the mechanism of filament severing. Nature 1993; 364:685-692.
56. Ohsawa M, Kimura H. Formation of vitamin D-binding protein-actin and binary and ternary plasma gelsolin-actin complexes in human serum. Biochim Biophys Acta 1989; 992:195-200.
57. Goldschmidt-Clermont PJ, Galbraith RM, Emerson DL, Nel AE, Werner PAM, Lee WM. Effects of ligand binding upon measurement of Gc by rocket immunoelectrophoresis: implications for protein determination and for studies of protein/ligand interactions. Electrophoresis 1985; 6:155-161.
58. Dueland S, Nenseter MS, Drevon CA. Uptake and degradation of filamentous actin and vitamin D-binding protein in the rat. Biochem J 1991; 274:237-241.
59. Herrmannsdoerfer AJ, Heeb GT, Feustel PJ, Estes JE, Keenan CJ. Minnear FL et al. Vascular clearance and organ uptake of G- and F-actin in the rat. Am J Physiol 1993; 265:G1071-G1081.
60. Imawari M, Kida K, Goodman DS. The transport of vitamin D and its 25-hydroxy metabolite in human plasma. Isolation and partial characterization of vitamin D and 25-hydroxyvitamin D binding protein. J Clin Invest 1976; 58:514-523.
61. Daiger SP, Schanfield MS, Cavalli-Sforza LL. Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. Proc Natl Acad Sci USA 1975; 72:2076-2090.
62. Haddad JG, Hu YZ, Kowalski MA, Laramore C, Ray K, Robzyk P et al. Identification of the sterol- and actin-binding domains of plasma vitamin D binding protein (Gc-globulin). Biochemistry 1992; 31:7174-7181.
63. Bouillon R, Van Baelen H, De Moor P. The measurement of the vitamin D binding protein in human serum. J Clin Endocrinol Metab 1977; 45:225-231.
64. Yamamoto N, Homma S. Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 1991; 88:8539-8543.
65. Yamamoto N. Kumashiro R. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of β-galactosidase of B cells and sialidase of T cells. J Immunol 1993; 151:2794-2802.
66. Homma S, Yamamoto M, Yamamoto N. Vitamin D-binding protein (group-specific component) is the sole serum protein required for macrophage activation after treatment of perotoneal cells with lysophophatidylcholine. Immunol Cell Biol 1993; 71:249-257.
67. Gomme PT, Bertolini J. Therapeutic potential of vitamin D-binding protein. Trends Biotechnol 2004; 22(7):340-345.
68. Gumireddy K, Reddy CD, Swamy N. Mitogen-activated protein kinase pathway mediates DBP-maf-induced apoptosis in RAW 264.7 macrophages. J Cell Biochem 2003; 90(1):87-96.
69. Yamamoto N, Naraparaju VR, Srinivasula SM. Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients. AIDS Res Hum Retroviruses 1995; 11:1373-1378.
70. Yamamoto N, Naraparaju VR, Asbell SO. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res 1996; 56:2827-2831.
71. Mohamad SB, Nagasawa H, Uto Y, Hori H. Tumor cell alpha-N-acetyl-galactosaminidase activity and its involvement in GcMAF-related macrophage activation. Comp Biochem Physiol A Mol Integr Physiol 2002; 132(1):1-8.
72. Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N. Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. J Natl Cancer Inst 2002; 94 (17):1311-1319.
73. Kalkunte S, Brard L, Granai CO, Swamy N. Inhibition of angiogenesis by vitamin D-binding protein: Characterization of anti-endothelial activity of DBP-maf. Angiogenesis 2005; 8(4):349-360.
74. Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK et al. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer 2006; 6:68.
75. Robbins RA, Hamel FG. Chemotactic factor inactivator interaction with Gc-globulin (vitamin D-binding protein). A mechanism of modulating the chemotactic activity of C5a. J Immunol 1990; 144:2371-2376.
76. Perez HD, Kelly E, Chenoweth D, Elfman F. Identification of the C5a des Arg cochemotaxin. Homology with vitamin D-binding protein (group-specific component globulin). J Clin Invest 1988; 82:360-363.
77. Piquette CA, Robinson-Hill R, Webster RO. Human monocyte chemotaxis to complement-derived chemotaxis is enhanced by Gc-globulin. J Leukoc Biol 1994; 55:349-354.
78. Kew RR, Fisher JA, Webster RO. Co-chemotactic effect of Gc-globulin (vitamin D binding protein) for C5a. Transient conversion into an active co-chemotaxin by neutrophils. J Immunol 1995; 155:5369-5374.
79. DiMartino SJ, Shah AB, Trujillo G, Kew RR. Elastase controls the binding of the vitamin D-binding protein (Gc- globulin) to neutrophils: a potential role in the regulation of C5a co- chemotactic activity. J Immunol 2001; 166(4):2688-2694.
80. Perez HD. Gc globulin (vitamin D-binding protein) increases binding of low concentrations of C5a des Arg to human polymorphonuclear leukocytes: an explanation for its cochemotaxin activity. Inflammation 1994; 18:215-220.
81. McVoy LA, Kew RR. CD44 and annexin A2 mediate the C5a chemotactic cofactor function of the vitamin D binding protein. J Immunol 2005; 175(7):4754-4760.
82. Meier U, Gressner O, Lammert F, Gressner AM. Gc-globulin: roles in response to injury. Clin Chem 2006; 52 (7):1247-1253.
83. Chujo T, Machii T, Tagawa S, Kuratsune H, Ueda E, Kimura H et al. Inhibition of human natural killer activity by antiserum against vitamin D-binding protein, a group-specific component (Gc). Clin Exp Immunol 1989:76:154-158.
84. Ades EW, Bosse D, Nicholson JKA, Galbraith RM. Interaction of Gc (vitamin-D binding protein) with membrane of activated natural cytolytic cells. Tokai J Exp Clin Med 1988; 13:293-297.
85. Williams MH, Van Alstyne EL, Galbraith RM. Evidence of a novel association of unsaturated fatty acids with Gc (vitamin D-binding protein). Biochem Biophys Res Comm 1999; 153(3):1019-1024.
86. Calvo M, Ena JM. Relations between vitamin D and fatty acid binding properties of vitamin D-binding protein. Biochem Biophys Res Comm 1989; 163(1):14-17.
87. Berger D, Beger HG, Evidence for endotoxin binding capacity of human Gc-globulin and transferrin. Clin Chim Acta. 1987: 163:289-299.
88. Berger D, Winter M, Beger HG. Influence of human transferrin and group-specific protein on endotoxicity in vitro. Clin Chim. Acta 1990; 189:1-6.
89. Sabbatini A, Petrini M, Mattii L, Arnaud P, Galbraith RM. Vitamin D binding protein is produced by human monocytes. FEBS Lett 1993; 323:89-92.
90. Petrini M, Allegrini A, Ambrogi F, Valentini P, Sabbatini A, Arnaud P et al. Binding of GC (VDBP) to membranes of human B lymphocytes following stripping of extant protein. J Endocrinol Invest 1995; 18:630-637.
91. Petrini M, Emerson DL, Galbraith RM. Linkage between surface immunoglobulin and cytoskeleton of lymphocytes may involve Gc protein. Nature 1983; 306:73-74.
92. Kew RR, Sibug MA, Liuzzo JP, Webster RO. Localization and quantitation of the vitamin D binding protein (Gc-globulin) in human neutrophils. Blood 1993; 82:274-283.
93. Guoth M, Murgia A, Smith RM, Prystowsky MB, Cooke NE, Haddad JG. Cell surface vitamin D-binding protein (Gc-globulin) is acquired from plasma. Endocrinology 1990:127:2313-2321.
94. Petrini M, Valentini P, Allegrini A, Sabbatini A, Testi R, Ambrogi F et al. Is binding of vitamin D binding protein related to cell differentiation? Leuk Res 1993; 17:561-565.
95. Swamy N, Ghosh S, Schneider GB, Ray R. Baculovirus-expressed vitamin D-binding protein-macrophage activating factor (DBP-maf) activates osteoclasts and binding of 25-hydroxyvitamin D(3) does not influence this activity. J Cell Biochem 2001; 81(3):535-546.
96. Goldschmidt-Clermont PJ, Galbraith RM, Emerson DL, Werner PAM, Nel AE, Lee WM. Accurate quantitation of native Gc protein in serum and estimation of endogenous Gc:G-actin complexes by rocket immunoelectrophoresis. Clin Chim Acta 1985; 148:173-183.
97. Lee WM, Galbraith RM, Watt GH, Hughes RD, McIntire DD, Hoffman BJ et al. Predicting survival in fulminant hepatic failure using serum Gc protein concentrations. Hepatology 1995; 21:101-105.
98. Lee WM, Emerson DL, Young WO, Goldschmidt-Clermont PJ, Jollow DJ, Galbraith RM. Diminished serum Gc (vitamin D-binding protein) levels and increased Gc:G-actin complexes in a hamster model of fulminant hepatic necrosis. Hepatology 1987; 7:825-830.
99. Young WO, Goldschmidt-Clermont PJ, Emerson DL, Lee WM, Jollow DJ, Galbraith RM. Correlation between went of liver damage in fulminant hepatic necrosis and complexing of circulating group-specific component (vitamin D-binding protein). J Lab Clin Med 1987: 110:83-90.
100. Jørgensen CS, Christiansen M, Nørgaard-Petersen B, Østergaard E, Schiødt FV, Laursen I et al. Gc-globulin (vitamin D-binding protein) levels: An inhibition ELISA assay for determination of the total concentration of Gc-globulin in plasma and serum. Scand J Clin Lab Invest 2004; 64:157-166.
101. Goldschmidt-Clermont P, Lee WM, Galbraith RM. Proportion of circulating Gc (vitamin D-binding protein) in complexed form: relation to clinical outcome in fulminant hepatic necrosis. Gastroenterology 1988; 94:1454-1458.
102. Vavrusa B, Cleve H, Constans J. A deficiency mutant of the Gc system. Hum Genet 1983; 65:102-107.
103. Walsh PG, Haddad JG. «Rocket» immunoelectrophoresis assay of vitamin D-binding protein (Gc globulin) in human serum. Clin Chem 1982; 28(8):1781-1783.
104. Bikle DD, Gee E, Halloran B, Haddad JG. Free 1,25-dibydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and subjects with liver disease. J Clin Invest 1984; 74(6):1966-1971.
105. Diamond T, Stiel D, Mason R, Lissner D, Bikle D. Wilson S et al. Serum vitamin D metabolites are not responsible for low turnover osteoporosis in chronic liver disease. J Clin Endocrinol Metab 1989; 69:1234-1239.
106. Wians FH, Lin W, Brown LP, Schiødt FV, Lee WM. Immunonephelometric quantification of group-specific component protein in patients with acute liver failure. Liver Transpl Surg 1997; 3(1):28-33.
107. Haughton MA, Mason RS. Immunonephelometric assay of vitamin D-binding protein. Clin Chem 1992; 38(9):1796-1801.
108. Hamashima Y, Kanazawa T, Hirata A, Yamai Y, Fujihara H, Sekine K et al. Measurement of vitamin D-binding protein in pleural fluids and sera by means of a turbidimetric immunoassay measuring system. Clin Chim Acta 2002; 321(1-2):23-28.
109. Lee WM, Emerson DL, Werner PAM, Arnaud P, Goldschmith-Clermont P, Galbraith RM. Decreased serum group-specific component protein levels and complexes with actin in fulminant hepatic necrosis. Hepatology 1985; 5:271-275.
110. Antoniades CG, Berry PA, Bruce M, Cross TS, Portal AJ, Hussain MJ et al. Actin-free serum Gc globulin levels closely mirror disease severity in both acute liver failure and chronic liver disease. Liver Transpl 2007;13:1254-1261
111. Bangert K, Rossen M, Uttenthal LO, Schiødt FV. Actin-free Gc-globulin serum levels predict survival in acetaminophen intoxication. Intensive Care Med, 32[S13], S205. 2006.
112. Clemmesen JO, Larsen FS, Ejlersen E, Schiødt FV, Ott P, Hansen BA. Haemodynamic changes after high-volume plasmapheresis in patients with chronic and acute liver failure. Eur J Gastroenterol Hepatol 1997: 9:55-60.
113. Tygstrup N, Larsen FS, Hansen BA. Treatment of acute liver failure by high volume plasmapheresis. In: Lee WM, Williams R, editors. Acute liver failure. Cambridge: Cambridge University Press, 1997: 267-277.
114. Schiødt FV, Lee WM. Management of acetaminophen toxicity. In: Krawitt EL, editor. Medical management of liver disease. New York: Marcel Dekker, 1999: 325-337.
115. Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet 1995; 346:547-552.
116. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003: 349(5):474-485.
117. Schiødt FV, Lee WM, Bondesen S, Ott P, Christensen E. Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. Aliment Pharmacol Ther 2002; 16(4):707-715.
118. Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology 2002: 35(4):876-882.
119. Schiødt FV, Bondesen S, Tygstrup N, Christensen E. Prediction of hepatic encephalopathy in paracetamol overdose: a prospective and validated study. Scand J Gastroenterol 1999; 34(7):723-728.
120. Schiødt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997; 337:1112-1117.
121. Larsen FS, Kirkegaard P, Rasmussen A, Hansen BA. The Danish liver transplantation program and patients with serious acetaminophen intoxication. Transplant Proc 1995; 27(6):3519-3520.
122. Makin AJ, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology 1995; 109:1907-1916.
123. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A. Davern TJ, Han SH et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137(12):947-954.
124. Knudsen TT, Thorsen S, Jensen SA, Dalhoff K, Schmidt LE, Becker U et al. Effect of intravenous N-acetylcysteine infusion on haernostatic parameters in healthy subjects. Gut 2005; 54(4):515-521.
125. Schmidt LE, Knudsen TT. Dalhoff K, Bendtsen F. Effect of acetylcysteine on prothrombin index in paracetamol poisoning without hepatocellular injury. Lancet 2002; 360(9340):1151-1152.
126. Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, editors. Progress in liver diseases. New York: Grune & Stratton, 1970: 282-298.
127. Ritt DJ, Whelan G, Werner DJ, Eigenbrodt EH, Schenker S, Combes B. Acute hepatic necrosis with stupor or coma. An analysis of thirty-one patients. Medicine 1969: 48:151-172.
128. Rakela J, Mosley JW, Edwards VM, Govindarajan S, Alpert E, the Acute Hepatic Failure Study Group. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. Dig Dis Sci 1991; 36:1223-1228.
129. Rakela J, Lange SM, Ludwig J, Baldus WP. Fulminant hepatitis: Mayo Clinic experience with 34 cases. Mayo Clin Proc 1985; 60:289-292.
130. Ranek L, Andreasen PB, Tygstrup N. Galactose elimination capacity as a prognostic index in patients with fulminant liver failure. Gut 1976; 17:959-964.
131. Bernal W, Wendon J, Rela M, Heaton N, Williams R. Use and outcome of liver transplantation in acetaminophen-induced acute liver failure. Hepatology 1998: 27:1050-1055.
132. Bismuth H, Samuel D, Castaing D, Williams R, Pereira SP. Liver transplantation in Europe for patients with acute liver failure. Sem Liver Dis 1996; 16(4):415-425.
133. Schiødt FV, Davern TJ, Obaid SA, McGuire B, Samuel G, Lee WM. Viral hepatitis-related acute liver failure. Am J Gastroenterol 2003; 98(2):448-453.
134. Larson AM, Poison J, Fontana RJ, Davern TJ, Lalani E, Hynan LS et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42(6):1364-1372.
135. Jollow DJ, Mitchell JR, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther 1973; 187:195-202.
136. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 1973; 187(l):211-217.
137. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439-445.
138. Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986; 6:648-651.
139. Pereira LLMB, Langley PG, Hayllar KM, Tredger JM, Williams R. Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators. Gut 1992; 33:98-102.
140. Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002; 359(9306):558-563.
141. Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999; 29(3):648-653.
142. Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 2002; 36:659-665.
143. Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology 2005; 41(1):26-31.
144. Schiødt FV, Ostapowicz G, Murray N, Satyanarana R, Zaman A, Munoz S et al. Alpha-fetoprotein and prognosis in acute liver failure. Liver Transpl 2006; 12(12):1776-1781.
145. Acharya SK, Dasarathy S, Kumer TL, Sushma S, Prasanna KSU, Tandon A et al. Fulminant hepatitis in a tropical population: clinical course, cause. and early predictors of outcome. Hepatology 1996; 23(6):1448-1455.
146. Pauwels A, Mostefa-Kara N, Florent C, Levy VG. Emergency liver transplantation for acute liver failure. Evaluation of London and Clichy criteria. J Hepatol 1993; 17:124-127.
147. Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria. J Hepatol 1997; 26:62-68.
148. Schiødt FV, Bangert K, Shakil AO, McCashland TM, Murray N. Hay JE et al. Actin-free Gc-globulin in 178 patients with acute liver failure as determined with a novel commercial ELISA kit. Liver Transpl 2007;13:1324-1329
149. Bailey B, Amre DK, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med 2003; 31(1):299-305.
150. Harrison PM, O'Grady JG, Keays RT, Alexander GJM, Williams R. Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ 1990; 301:964-966.
151. Schiødt FV, Lee WM. Fulminant liver disease. Clin Liver Dis 2003; 7(2):331-49, vi.
152. Goka AKJ, Wendon JA, Williams R. Fulminant hepatic failure, endogenous endotoxemia, and multiple systems organ failure. In: Matuschak GM, editor. Multiple systems organ failure. Hepatic regulation of systemic host defense. New York: Marcel Dekker, Inc., 1993: 215-228.
153. Riordan SM, Williams R. Mechanisms of hepatocyte injury, multiorgan failure. and prognostic criteria in acute liver failure. Semin Liver Dis 2003; 23(3):203-215.
154. Hay JE. Acute Liver Failure. Curr Treat Options Gastroenterol 2004; 7(6):459-469.
155. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32(4 Pt 1):734-739.
156. Vaquero J, Poison J, Chung C, Helenowski I, Schiødt FV. Reisch J, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003; 125(3):755-764.
157. Ware AJ, D'Agostino AN, Combes B. Cerebral edema: a major complication of massive hepatic necrosis. Gastroenterology 1971; 61:877-884.
158. Biel AT. Cerebral edema and intracranial hypertension in acute liver failure: distinct aspects of the same problem. Hepatology 1991: 13:376-379.
159. Beal AL, Cerra FB. Multiple organ failure syndrome in the 1990s. JAMA 1994; 271:226-233.
160. Peltekian KM, Levy GA. Role of cytokines and immune mechanisms in acute liver failure. In: Lee WM, Williams R, editors. Acute liver failure. Cambridge: Cambridge University Press, 1997: 67-78.
161. Bihari D, Gimson A, Lindridge J. Williams R. Lactic acidosis in fulminant hepatic failure. Some aspects of pathogenesis and prognosis. J Hepatol 1985; 1:405-416.
162. Bihari D, Gimson AE, Waterson M, Williams R. Tissue hypoxia during fulminant hepatic failure. Crit Care Med 1985; 13:1034-1039.
163. Dahl B, Schiødt FV, Ott P, Wians F, Lee WM, Balko J et al. Plasma concentration of Gc-globulin is associated with organ dysfunction and sepsis after injury. Crit Care Med 2003: 31(1):152-156.
164. Matkowitz R, Hartig W, Junghans P, Slowig M, Bornhak H, Faust H et al. Protein turnover in liver failure - determination using the stable isotope 15N [German]. Leber Magen Darm 1984; 14:83-89.
165. Guha C, Osawa M, Werner PA, Galbraith RM, Paddock-GV. Regulation of human Gc (vitamin D-binding) protein levels: hormonal and cytokine control of gene expression in vitro. Hepatology 1995; 21:1675-1681.
166. Sekiyama KD, Yoshiba M, Thomson AW. Circulating proinflammatory cytokines (IL-1β, TNF-α, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol 1994; 98:71-77.
167. Milland J, Tsykin A, Thomas T, Aldred AR, Cole T, Schreiber G. Gene expression in regenerating and acute-phase rat liver. Am J Physiol 1990; 259:G340-G347.
168. Kondrup J, Almdal T, Vilstrup, H, Tygstrup N. High volume plasma exchange in fulminant hepatic failure. Int J Artif Organs 1992; 15:669-676.
169. Lee WM, Schiødt FV. Fulminant hepatic failure. In: Schiff, ER, Sorrell MF, Maddrey WC, editors. Schiffs Diseases of the Liver. Philadelphia Lippincott-Raven Publishers, 1999: 879-895.
170. Yamamoto N, Willett NP, Lindsay DD. Participation of serum proteins in the inflammation-primed activation of macrophages. Inflammation 1994; 18:311-322.
171. Yamamoto N, Naraparaju VR. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res 1997; 57:2187-2192.
172. Imawari M, Hughes RD, Gove CD, Williams R. Fibronectin and Kupffer cell function in fulminant hepatic failure. Dig Dis Sci 1985; 30:1028-1033.
173. Canalese J, Gove CD, Gimson AES, Wilkinson SP, Wardle EN, Williams R. Reticuloendothelial system and hepatocyte function in fulminant hepatic failure. Gut 1982; 23:265-269.
174. Bouillon R, Auwerx J, DeKeyser L, Fevery J, Lissens W, De Moor P. Serum vitamin D metabolites and their binding protein in patients with liver cirrhosis. J Clin Endocrinal Metab 1984; 59:86-89.
175. Masuda S, Okano T, Osawa K, Shinjo M, Suematsu T, Kobayashi T. Concentrations of vitamin D-binding protein and vitamin D metabolites in plasma of patients with liver cirrhosis. J Nutr Sci Vitaminol 1989; 35:225-234.
176. Friend PJ, Imber CJ. Current status of liver transplantation. Methods Mol Biol 2006; 333:29-46.
177. Kashiwagi N, Groth CG, Starzl TE. Changes in haptoglobin and group specific component after orthotopic liver homotransplantation in humans. Proc Soc Exp Biol Med 1968; 128:247-250.
178. De Riberolles C, Franco D, Lecompte Y, Blondeau B, Chauvaud S, Grange D et al. Early recovery of albumin synthesis after liver transplantation. Eur Surg Res 1975; 7:164-169.
179. Rake MO, Williams R, Freeman T, McFarlane AS. Protein synthesis by the liver after transplantation. Lancet 1970; ii:341-342.
180. Lee WM, Reines D, Watt GH, Cook JA, Wise WC, Halushka PV et al. Alterations in Gc levels and complexing in septic shock. Circ Shock 1989; 28:249-255.
181. Watt GH, Ashton SH, Cook JA, Wise WC. Halushka PV, Galbraith RM. Alterations in plasma levels and complexing of Gc (vitamin D-binding protein) in rats with endotoxic shock. Circ Shock 1989; 28:279-291.
182. Polberger SK, Fex G, Raiha NC. Concentrations of twelve plasma proteins at birth in very low birthweight and in term infants. Acta Paediatr Scand 1990; 79(8-9):729-736.
183. Hillman LS, Haddad JG. Serial analyses of serum vitamin D-binding protein in preterm infants from birth to postconceptual maturity. J Clin Endocrinol Metab 1983; 56(1):189-191.
184. Schmidt-Gayk H, Grawunder C, Tschope W, Schmitt W, Ritz E, Pietsch V et al. 25-hydroxy-vitamin-D in nephrotic syndrome. Lancet 1977; 2:105-108.
185. Dahl B, Schiödt FV, Kiaer T, Ott P, Bondesen S, Tygstrup N. Serum Gc-globulin in the early course of multi-trauma. Crit Care Med 1998; 26(2):285-289.
186. Dahl B, Schiödt FV, Nielsen M, Kiær T, Williams JG, Ott P. Admission levels of Gc-globulin predicts outcome after multiple trauma. Injury 1999; 30:275-281.
187. Dahl B, Schiodt FV, Rudolph S, Ott P, Kiaer T, Heslet L. Trauma stimulates the synthesis of Gc-globulin. Intensive Care Med 2001: 27(2):394-399.
188. Wandall JH. Concentratlofis of serum proteins during and immediately after surgical trauma. Acta Chir Scand 1974:140:171-179.
189. Dahl B, Schiødt FV, Gehrchen PM, Ramlau J, Kiaer T, Ott P. Gc-globulin is an acute phase reactant and an indicator of muscle injury after spinal surgery. Inflamm Res 2001: 50(1):39-43.
190. Imawari M, Kozawa K, Akanuma Y, Koizumi S, Itakura. H, Kasaka K. Serum 25-hydroxyvitamin D and vitamin D-binding protein levels and mineral metabolism after partial and total gastrectomy. Gastroenterology 1980; 79(2):255-258.
191. Dibble JB, Sheridan P, Losowsky MS. A survey of vitamin D deficiency in gastrointestinal and liver disorders. Q J Med 1994; 53(209):119-134.
192. Parillo JE. Mechanisms of disease: pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328:1471-1477.
193. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Soclety of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874.
194. Martin C, Boisson C, Haccoun M, Thomachot L, Mege J-L. Patterns of cytokine evolution (tumor necrosis factor-a and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 1997; 25:1813-1819.
195. Ito H, Kambe H, Kimura Y, Nakamura H, Hayashi E, Kishimoto T et al. Depression of plasma gelsolin level during acute liver injury. Gastroenterology 1992; 102:1686-1692.
196. Schiødt FV, Clemmesen JO, Lin W, Ott P, Lee WM. Gelsolin in acute liver failure. Hepatology 28[4], 333A. 1998. [Abstract]
197. Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med 1997; 25:591-598.
198. Huang S, Rhoads SL, DiNubile MJ. Temporal association between serum gelsolin levels and clinical events in a patient with severe Falciparum malaria. Clin Inf Dis 1997; 24:951-954.
199. Smith DB, Janmey PA, Sherwood JA, Howard RJ, Lind SE. Decreased plasma gelsolin levels in patients with Plasmodium falciparum malaria: a consequence of hemolysis? Blood 1988; 72:214-218.
200. Mounzer KC, Moncure M, Smith YR, DiNubile MJ. Relationship of ad mission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med 1999; 160:1673-1681.
201. Dahl B, Schiødt FV, Ott P, Gvozdenovic R. Yin HL, Lee WM. Plasma gelsolin is reduced in trauma patients. Shock 1999; 12(2):102-104.
202. Asch HL, Head K, Dong Y, Natoli F, Winston JS, Connolly JL et al. Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res 1996; 56:4841-4845.
203. Asch HL, Winston JS, Edge SB, Stomper PC, Asch BB. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion. Breast Cancer Res Treatm 1999; 55:179-188.
204. Dosaka-Akita H, Hommura F, Fujita H, Kinoshita I, Nishi M, Morikawa T et al. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers, Cancer Res 1998; 58:322-327.
205. Lind SE, Smith DB, Janmey PA, Stossel TP. Depression of gelsolin levels and detection of gelsolin-actin complexes in plasma of patients with acute lung injury. Am Rev Respir Dis 1989; 138:429-434.
206. DiNubile MJ, Stossel TP, Ljunghusen OC, Ferrara JL, Antin JH. Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood 2002; 100(13):4367-4371.
207. Löfberg M, Paunio T, Talitela, R, Kiuru S, Somer H. Serum gelsolin and rhabdomyolysis. J Neurolog Sci 1998; 157:187-190.
208. Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 2007;35:849-855.
209. Jorgensen CS, Christiansen M, Laursen I, Krogsoe LB, Hojrup P. Blou L et al. Large-scale purification and characterization of non-glycosylated Gc globulin (vitamin D-binding protein) from plasma fraction IV. Biotechnol Appl Biochem 2006: 44(Pt 1):35-44.
210. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15:45-52.
211. Tang WX, Bazaraa HM, Magiera H, Cooke NE, Haddad JG. Electrophoretic mobility shift assay identifies vitamin D binding protein (Gc-globulin) in human, rat, And mouse sera. Anal Biochem 1996; 237:245-251.